Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0001209191-23-050274)

Filing Details

Accession Number:: 0001209191-23-050274
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-09-21 16:30:38
Reporting Period:: 2023-09-20

Accepted Time:: 2023-09-21 16:30:38
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1231457	Genelux Corp	GNLX	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1937485	Sean Ryder	C/O Genelux Corporation 2625 Townsgate Road, Suite 230 Westlake Village CA 91361	General Counsel	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-09-20	10,000	$6.00	10,572	No	4	M	Direct
Common Stock	Disposition	2023-09-20	10,000	$30.00	572	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2023-09-20	10,000	$0.00	10,000	$6.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
140,000		2031-10-03	No	4	M	Direct

Footnotes

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2023.
25% of the shares shall vest on October 4, 2022, and the remaining shares shall vest in 36 equal monthly installments thereafter.